Cabergoline for Preventing Breast Symptoms After Abortion or Pregnancy Loss

This study is looking at whether a medication called cabergoline can help prevent breast symptoms like engorgement and milk leakage after an abortion or pregnancy loss. These symptoms can happen because the body starts to prepare for breastfeeding even with a pregnancy loss. Participants will receive either a single dose of cabergoline or a placebo (a pill with no active medicine) about an hour after their procedure. Researchers want to see if cabergoline reduces the number of people who experience breast symptoms and how severe those symptoms are. You might be able to join if you are 18 or older, 12 to 18 weeks pregnant, and having an abortion or pregnancy loss at Maimonides Medical Center. The study is currently unclear about its recruitment status and plans to enroll 348 participants.

Study design
This is an interventional study where participants will be randomly assigned to receive either cabergoline or a placebo. The study plans to enroll 348 participants.
What's involved
Participants will receive a single oral dose of medication approximately one hour after their procedure. They will also need to complete study surveys.
Compensation
Not stated in the trial record.
Follow-up
Researchers will measure breast symptoms 4 days after the abortion or pregnancy loss.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07492160

Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms

Recruiting
PHASE2Ages 18+InterventionalTreatment
Maimonides Medical Center
~348 participants
Updated 2026-03-25 on ClinicalTrials.gov
What's tested:CabergolinePlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of Participants With Breast Symptoms 4 Days After Abortion or Pregnancy Loss
Measured over 4 days after abortion or pregnancy loss
Pregnancy
Abortion
1 sites across 1 states
New York1
  • June Ng, MD · PRINCIPAL_INVESTIGATOR · Maimonides Medical Canter

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Pregnant people aged 18 years or older
Gestational age between 12 and 18 weeks
Undergoing treatment for spontaneous or induced abortion at Maimonides Medical Center
Able to provide informed consent
Willing and able to complete study surveys

Exclusion

Prior mastectomy
Currently breastfeeding
Current use of a dopamine agonist or dopamine antagonist medication
Known contraindication to Cabergoline according to the medication prescribing information
  • Proportion of Participants With Breast Symptoms 4 Days After Abortion or Pregnancy Loss4 days after abortion or pregnancy loss

    The proportion of participants reporting any breast symptoms, including breast engorgement, milk leakage, tenderness, or need for pain relief, assessed using the Bristol Breast Symptoms Inventory.